Summary
Datamonitor's Cytogen Corporation - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Cytogen is a specialty pharmaceutical company focused on building, developing, and commercializing a portfolio of oncology products for the treatment and care of cancer patients. The company currently markets Quadramet (samarium Sm-153 lexidronam injection), Prostascint (capromab pendetide), and Soltamox (tamoxifen citrate) to the US oncology market. Cytogen is headquartered in Princeton, New Jersey and employed 95 people as of December 2006. The company recorded revenues of $17 million during the fiscal year ended December 2006, an increase of 8.8% over 2005. The operating loss of the company was $30 million during fiscal year 2006, as compared to $29 million in 2005. The net loss in fiscal year 2006 was $29 million, as compared to $28 million in 2005.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available
|
